HeartBeat.bio AG

HeartBeat.bio is building the worldwide first high-throughput human organoid cultivation, screening and AI-supported data analysis solution for developing first-in-class drugs to treat heart failure faster, less expensively and with a higher probability of success in clinical trials. The so-called Cardioid Drug Discovery Platform relies on self-assembling, highly reproducible cardiac organoids which recapitulate the human physiology and enable modeling of heart diseases in a way not achieved with other in-vitro systems. Currently, HeartBeat.bio is focused on drug-induced and different sub-types of genetic cardiomyopathies, followed by programs in diabetic cardiomyopathy, myocardial infarction, and cardiac remodeling. HeartBeat.bio was founded in 2021 based on...

Cardiac organoids,human 3d disease modelling ,high-throughput drug discovery platform,cardiac drug discovery,heart failure,cardiomyopathy,heart regeneration,myocardial infarction,cardiotoxicity,cardio-oncology,and ips cells

Heartbeat.bio ag's HQ phone number is +49 89 2102280

Heartbeat.bio ag's revenue is 11m - 100m

Heartbeat.bio ag has 11 - 50 employees.